---
title: "These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286141162.md"
description: "Liquidia Corp (LQDA) reported strong Q1 results with earnings of 52 cents per share and sales of $132.865 million, surpassing analyst expectations. Following this, analysts raised their price targets: Wells Fargo's Benjamin Burnett increased it from $51 to $62, while HC Wainwright's Andrew S. Fein raised it from $55 to $67. Liquidia shares rose 3.1% to $54.80 after the announcement."
datetime: "2026-05-12T18:06:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286141162.md)
  - [en](https://longbridge.com/en/news/286141162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286141162.md)
---

# These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results

**Liquidia Corp** (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.

Liquidia reported quarterly earnings of 52 cents per share which beat the analyst consensus estimate of 41 cents per share. The company reported quarterly sales of $132.865 million which beat the analyst consensus estimate of $116.675 million.

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent.”

Liquidia shares gained 3.1% to trade at $54.80 on Tuesday.

These analysts made changes to their price targets on Liquidia following earnings announcement.

-   Wells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $51 to $62.
-   HC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $55 to $67.

**Considering buying LQDA stock? Here’s what analysts think:**

_Photo via Shutterstock_

### Related Stocks

- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)